TrialBMJ open2025

Cost-effectiveness analysis of penpulimab combined with paclitaxel and carboplatin as a first-line treatment for metastatic squamous non-small cell lung cancer in China.

Liangxiao Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.